65,437 trials
Healthy Japanese Children Age 7 Years Through 18 Years
Primary: the Incidence of Laboratory-confirmed Influenza Infection (Matched Strain) — 0; 1 Participants
Colorectal Neoplasms · Digestive System Diseases · Colonic Diseases
Primary: Sensitivity and Specificity of the Exact CRC Screening Test With Comparison to Colonoscopy, Both With Respect to Cancer. — 92.3; 73.8; 93.3; 73.3 percent
Presbyopia
Primary: Percentage of Participants With at Least a 2 Line Improvement From Baseline in Uncorrected Near Visual Acuity (UNVA) in the Non-Dominant Eye — 46.7; 70.6; 56.3; 68.8…
Dry Eye Syndromes
Primary: Percentage of Patients With a Presence of Matrix Metalloproteinase-9 (MMP-9) in the Study Eye — 36.2 percentage of participants
Chronic Lymphocytic Leukemia
Primary: Overall Response Rate — 53 percentage of participants
Human Immunodeficiency Virus (HIV) Infections · Acquired Immunodeficiency Syndrome (AIDS) Virus
Primary: Virologic Response (Food Drug and Administration [FDA] Snapshot, Switch = Failure) — 87.0; 95.0 Percentage of Participants — p=0.2331
Non-myeloid Malignancies · Chemotherapy Induced Anaemia
Primary: Change in Hb Concentration — 0.48; 0.44 g/dL
Schizophrenia
Primary: Change From Baseline to Week 28 in Quality of Life Scale (QLS) Total Score — 7.47; 2.80 units on a scale — p=0.036
Anemia
Primary: Percentage of Participants Maintaining Average Hemoglobin (Hb) Concentration Within the Target Range — 77.1; 88.5; 90.9; 84.3 percentage of participants
Major Depressive Disorder · Depression · Depressive Symptoms
Primary: Change in Brachial Flow-Mediated Dilation (FMD) From Pre- to Post- Treatment — -1.18; 0.79 % change in brachial diameter — p=.474
Kidney Disease, Chronic
Primary: Average Dose of MIRCERA at Entry Level — 94 microgram (µg)
Waldenstrom's Macroglobulinemia · Non-Hodgkin's Lymphoma · Hodgkin's Disease
Primary: Number of Participants With Dose-limiting Toxicities (DLTs) — 1; 0; 0; 0 participants
Iron Deficiency Anemia · Chronic Kidney Disease
Primary: Change in Hemoglobin (Hb) Concentration From Baseline to Week 4. — 0.57; 0.35 g/dL
Multiple Myeloma
Primary: Best Overall Response Rate (ORR) in the Response Evaluable Subset Population — 16.1; 39.6; 53.0 percentage of participants
Primary Immunodeficiency Diseases (PID)
Primary: Validated Acute Serious Bacterial Infection (VASBI) Rate — 0.025 Estimated infections/year — p=<0.0001